Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Ltd. executive Tang Kaiyang filed an initial Form 3 disclosing indirect holdings of employee stock options on the company’s Class A Ordinary Shares. The filing lists several option grants held through an ESOP, with exercise prices of $1.80 and $1.10 per share and expiration dates in 2030. These entries are reported as holdings rather than new purchases or sales, establishing a baseline view of this officer’s existing derivative position in the stock.
Adlai Nortye Ltd. director Ji Ping has filed a Form 3 insider report for issuer ANL. The filing data identifies Ji Ping as a director and shows no reported transactions, share acquisitions or dispositions, and no derivative positions in the summarized period.
Adlai Nortye Ltd. files Amendment No. 2 to its Form F-3 registration statement (File No. 333-294173) dated April 24, 2026 to furnish legal opinions as Exhibits 5.1 and 23.3 and to update Part II exhibit indexing and signatures. The prospectus in Part I remains unchanged.
Adlai Nortye Ltd. is registering a shelf of up to $600,000,000 of securities and registration for resale of up to 98,577,627 Class A ordinary shares (represented by 32,859,209 ADSs) by selling shareholders.
The prospectus states the company will not receive proceeds from sales by the selling shareholders; the offering may include ADSs, ordinary shares, debt securities, warrants, rights and units and may be sold on Nasdaq or in private transactions. The filing discloses recent private placements that raised approximately $140.0M in February 2026 and $150.0M in April 2026 and lists Nasdaq last sale price of $16.60 per ADS as of April 20, 2026.
Adlai Nortye Ltd. entered into a Securities Purchase Agreement for a private placement of its equity. The company agreed to sell up to 33,962,265 Ordinary Shares, equivalent to 11,320,755 ADSs, at a purchase price of $13.25 per ADS (about $4.4167 per Ordinary Share). The deal is conducted under a private offering exemption and includes customary closing conditions, legal opinions, lock-up agreements from executives and key shareholders, and detailed investor representations. Purchasers receive registration rights requiring Adlai Nortye to file and seek effectiveness of a resale registration statement within defined deadlines so investors can later resell their shares in the public market.
Adlai Nortye Ltd., a Cayman Islands holding company with operations in the U.S. and mainland China, files its annual Form 20-F, highlighting its ADS listing on Nasdaq and a dual-class share structure totaling 120,000,803 ordinary shares as of December 31, 2025.
The report explains heavy reliance on subsidiaries for cash, detailed intercompany loans and capital contributions, and the impact of PRC foreign exchange and tax rules on upstreaming funds. It also stresses regulatory risks from the HFCAA, evolving Chinese oversight of overseas listings, and extensive intellectual property and clinical-development uncertainties for its drug pipeline.
Adlai Nortye Ltd. announced several leadership changes effective April 1, 2026. Archie Tse, M.D., Ph.D., was appointed President while continuing as Head of Research and Development, a role he has held since March 2024. His background includes senior R&D positions at multinational pharmaceutical companies.
The Board also appointed Dr. Ye as Chief Financial Officer, in addition to his responsibilities for business development and global commercialization strategy, after serving as interim CFO since January 2025. He brings experience in business development and commercial leadership across the Asia-Pacific region.
Current President Dr. Kaiyang Tang retired from the president role on April 1, 2026 and will remain as a Corporate Strategy Professor to support a smooth transition. The company states his retirement does not affect operations in finance, investor relations, or public relations, and that he has no disputes or disagreements with the company.
Adlai Nortye Ltd. filed a Form F-3 shelf registration to offer up to US$600,000,000 of Class A ordinary shares and to register for resale up to 64,615,386 Class A ordinary shares (represented by 21,538,462 ADSs), from time to time after the effective date. The prospectus states the selling shareholders’ sales will provide no proceeds to the company, and that ADSs trade on Nasdaq under the symbol ANL. The prospectus describes the securities, dual-class share structure, risk factors including HFCAA-related delisting risk, and that specific offering terms will be provided in prospectus supplements.
Adlai Nortye Ltd. reported that the first patient has been dosed in a global Phase 1 clinical trial of AN9025, its oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. This first-in-human, multicenter, open-label study will assess safety, tolerability, pharmacokinetics and early anti-tumor activity.
The trial is being run as a multi-regional clinical trial in collaboration with ASK Pharm, with Adlai Nortye holding rights to AN9025 outside mainland China, Hong Kong and Macao. AN9025 is part of the company’s broader oncology pipeline, which also includes next-generation cancer immunotherapies and additional RAS-targeting candidates.